Brief: Calidi Biotherapeutics Announces Strategic Partnership With Transferai
29/04/2026 13:19
April 29 (Reuters) - Calidi Biotherapeutics Inc CLDI.A: CALIDI BIOTHERAPEUTICS ANNOUNCES STRATEGIC PARTNERSHIP WITH TRANSFERAI TO DRIVE EFFICIENCIES IN THE IND SUBMISSION PROCESS FOR CLD-401 USING AGENTIC AI CALIDI BIOTHERAPEUTICS INC - EXPECTS CLD-401 IND FILING BY YEAR END Source text: ID:nGNX2qjzZg Further company coverage: CLDI.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Calidi Biotherapeutics
See all newsBrief: Calidi Biotherapeutics Announces Strategic Partnership With Transferai
Brief: Calidi Biotherapeutics Announces Partnership With Avance Clinical To Facilitate Australian Regulatory Approval
Brief: Calidi Biotherapeutics Announces Pricing Of $5.2 Million Underwritten Public Offering
Brief: Calidi Biotherapeutics Eliminates Chief Legal Officer Position - SEC Filing
Brief: Calidi Biotherapeutics Receives FDA Fast Track Designation For Cld-201 (Supernova), A First-In-Class Stem-Cell Loaded Viral Therapy For The Treatment Of Patients With Soft Tissue Sarcoma